期刊论文

中文

热带医学杂志

1672-3619

2016

16

7

859-862

江门市科技局项目（江科（2015）73号-11）；

本校为第一机构

目的：观察扶正化瘀胶囊联合核苷（酸）类似物（NAs）治疗NAs单药治疗后获得完全病毒学应答，但肝纤维化指标仍改善不佳的代偿期乙肝肝硬化患者的1年疗效。方法将已接受NAs初始治疗至少2年，获得完全病毒学应答6个月以上，但肝纤维化指标仍改善不佳的代偿期乙肝肝硬化患者100例随机分为试验组和对照组，每组50例。试验组给予NAs治疗，同时联合扶正化瘀胶囊治疗，对照组则继续单用NAs治疗，疗程均为48周。观察治疗前后肝功能、HBV-DNA定量、透明质酸（HA）、Ⅲ型前胶原（PCⅢ）、Ⅳ型胶原（ⅣC）、层黏蛋白（LN）、肝脾B超的变化，部分患者行肝穿检查。结果基线时两组以上观察指标差异均无统计学...

Objective To investigate the one year efficacy of Fuzhenghuayu (FZHY) Capsules combined with nucleos(t)ide analogues(NAs) in patients with hepatitis B cirrhosis compensatory phase. Methods One hundred patients with HBV related liver cirrhosis who had received NAs for more than 2 years and achieved sustained virological response (SVR) but with abnormal serum markers of liver fibrosis were randomly divided into two groups:NAs plus FZHY capsule and NAs only for 48 weeks. Liver function, HBV-DNA level, serum fibrosis markers [hyaluronic acid (HA), ...